BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · | ||||||
| · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| · · U.S. $ in thousands | ||||||
| Cash flows from operating activities: | | | ||||
| | | | | | | |
| Net loss | | $(11,623) | | $(17,192) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation | | 240 | | 265 | ||
| Stock-based compensation related to options granted to employees and directors | | 750 | | 1,490 | ||
| Change in operating lease liability, net | | 54 | | 155 | ||
| Decrease (increase) in prepaid expenses and other accounts receivable | | | 401 | | | (475) |
| Increase (decrease) in trade payables | | 1,126 | | (1,270) | ||
| Gain on change in fair value of warrants (Note 7) | | (147) | | (4,525) | ||
| Increase (decrease) in employees related liability and accrued expenses | | 106 | | | 1,094 | |
| Total net cash used in operating activities | | $(9,093) | | $(20,458) | ||
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended | ||||||
| · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| | | U.S. $ in thousands | ||||
| Cash flows from investing activities: | | | | | | |
| | | | | | | |
| Purchase of property and equipment | | | 12 | | | (18) |
| Changes in short-term deposit | | | — | | | 2,211 |
| Total net cash provided by investing activities | | $12 | | $2,193 | ||
| | | | | | | |
| Cash flows from financing activities: | | | | | | |
| Proceeds from issuance of shares in at-the-market (ATM) offering (Note 8) | | | 4,323 | | | 11,881 |
| Proceeds from Issuance of shares for private placement (Note 8) | | | 3,644 | | | 7,097 |
| Total net cash provided by financing activities | | $7,967 | | $18,978 | ||
| Increase (decrease) in cash and cash equivalents | | | (1,114) | | | 713 |
| | | | | | | |
| Cash, cash equivalents and restricted cash at the beginning of the period | | $1,485 | | $772 | ||
| | | | | | | |
| Cash, cash equivalents and restricted cash at end of the period | | $371 | | $1,485 | ||
| | | | | |
|---|---|---|---|---|
| · · Year ended | ||||
| · · December 31, | ||||
| · 2024 · 2023 | ||||
| Non-Cash Activities: · · USD in thousands | ||||
| ROU asset decreased, resulted from lease modification (Note 4) | | — | | 1,695 |
| Lease liability decreased, resulted from lease modification (Note 4) | | — | | 1,395 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.